IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 24, Issue 11 Ser. 2 (November. 2025), PP 27-31
www.iosrjournals.org

New Imaging Techniques For Glaucoma: A Review

Omaka AU, Ezeigbo AC
Department Of Optometry, Abia State University, Uturu, Nigeria

***Abstract**:*
***Background**: Glaucoma is a leading cause of irreversible blindness worldwide, characterized by progressive optic neuropathy. Early detection and monitoring are crucial, as structural damage often precedes functional vision loss. Traditional methods like intraocular pressure measurement and standard automated perimetry have limitations in sensitivity and subjectivity. This review synthesizes the current evidence on new imaging technologies that offer potential for earlier, more objective diagnosis and monitoring of glaucomatous changes.*
***Materials and Methods**: This narrative review was conducted by comprehensively examining recent scientific literature and clinical studies on emerging ocular imaging technologies. The focus was on techniques developed or significantly advanced since the mid-1990s, including various forms of optical coherence tomography (OCT), adaptive optics, and metabolic imaging. Their principles, advantages, and applications in visualizing the optic nerve head and retinal nerve fiber layer were analyzed and compared.*
***Results:** Advanced imaging techniques demonstrate significant potential. Swept-Source OCT provides deeper penetration and higher-quality images of the posterior pole[1]. Adaptive Optics enables visualization of individual retinal nerve fiber bundles[2]. Wide-field and hand-held OCT increase diagnostic scope and accessibility[3]. Techniques like Flavoprotein Fluorescence imaging show promise in detecting metabolic stress in retinal ganglion cells[4]. Furthermore, the integration of Artificial Intelligence with imaging data is improving diagnostic accuracy and risk prediction for glaucoma progression[5].*
***Conclusion**: New imaging techniques provide powerful, objective tools for the detailed assessment of glaucomatous structural damage. They hold the promise of revolutionizing glaucoma management by enabling earlier detection, more precise monitoring of progression, and better evaluation of treatment efficacy, potentially preventing vision loss through timely intervention.*
***Key Word:** Glaucoma; Optical Coherence Tomography; Adaptive Optics; Retinal Nerve Fiber Layer; Optic Nerve Head; Diagnostic Imaging.*

Date of Submission: 26-10-2025 Date of Acceptance: 06-11-2025

I. Introduction

Glaucoma is a multifactorial optic neuropathy and a leading cause of global irreversible blindness, affecting an estimated 70 million people[6]. It is characterized by the progressive loss of retinal ganglion cells (RGCs) and their axons, leading to distinct structural changes in the optic nerve head (ONH) and retinal nerve fiber layer (RNFL), which ultimately result in visual field defects. Elevated intraocular pressure (IOP) remains the primary and only modifiable risk factor[1]; however, a significant proportion of patients present with normal IOP, underscoring the complexity of the disease. The current reference standard for diagnosis and monitoring relies heavily on functional assessment via standard automated perimetry (SAP). However, SAP is subjective, requires patient cooperation, and often identifies functional loss only after substantial, irreversible structural damage has occurred[7]. This diagnostic lag highlights the critical need for objective, sensitive, and reproducible methods to detect glaucomatous changes at their earliest stages. The past few decades have witnessed rapid advancements in ocular imaging technologies. Moving beyond traditional techniques like fundus photography and confocal scanning laser ophthalmoscopy[10], new modalities offer unprecedented capabilities[8]. This review aims to provide a comprehensive overview of these emerging imaging techniques, including Swept-Source OCT, Adaptive Optics, wide-field imaging, and metabolic imaging, evaluating their principles, clinical applications, advantages, and potential to reshape the early diagnosis and management of glaucoma.



Figure 1. Pathophysiology of Glaucoma



Figure 2. Progressive Loss of GCC/RNFL over time

II. Material And Methods

This study is a comprehensive narrative review based on a thorough analysis of existing scientific literature. A non-systematic search was conducted using major academic databases (e.g., PubMed, Google Scholar) to identify relevant peer-reviewed articles, clinical trials, and review papers published primarily from the mid-1990s to the present. The search terms included "glaucoma imaging," "optical coherence tomography," "adaptive optics," "scanning laser polarimetry," "flavoprotein fluorescence," and "artificial intelligence in glaucoma". Inclusion criteria focused on studies describing new or significantly advanced in vivo imaging technologies for structural and functional assessment of the ONH and RNFL in glaucoma. The review synthesizes evidence on the technological principles, diagnostic accuracy, and clinical utility of these techniques, providing a qualitative summary of the current state of the art and future directions in glaucoma imaging.

TABLE 1. THE EVOLUTION OF OCT IMAGING PLATFORMS

Imaging Platform	Scan Speed (A-scans per second)	Axial Image Resolution (µm)	Anatomy Imaged
TD-OCT	400	10	Vitreoretinal interface to RPE
SD-OCT	27,000 to 60,000	5 to 7	Posterior vitreal cortex to sclera*
SS-OCT	100,000 to 400,000	5 to 7	Posterior vitreal cortex to sclera
OCT-A	≥70,000	~5	Vascular structures

* To image the sclera, a special setting is used for SD-OCT that sacrifices posterior vitreal cortex and inner retinal layers to obtain the scan; SS-OCT does not suffer this compromise.

TABLE 2. MACULAR THICKNESS PARAMETERS FOR VARIOUS OCT INSTRUMENTS[3,11-13]

Instrument	Macular Thickness Measurements
RTVue-100 (OptoVue)	Ganglion Cell Complex (GCC) = RNFL + GCL + IPL layers
Cirrus HD-OCT (Carl Zeiss Meditec)	Ganglion Cell Analysis (GCA) = Macular RNFL, GCL + IPL, GCC
Spectralis (Heidelberg)	Posterior Pole Asymmetry Analysis (PPAA)
Maestro (Topcon)	GCC = ILM to IPL/INL

Figure 3. Diagnostic Variabilities of the Different platforms of OCT

III. Result

The evaluation of new imaging techniques reveals a diverse and rapidly evolving landscape. The findings are categorized and summarized below:

Advancements in Optical Coherence Tomography (OCT)

Swept-Source OCT (SS-OCT): This technology utilizes a longer-wavelength, tunable laser light source, which provides significantly improved image penetration and reduced scattering. This allows for superior visualization of deep ocular structures, including the lamina cribrosa, and yields higher-quality images of the ONH and RNFL compared to earlier spectral-domain OCT[1].



Figure 4 Showing SS-OCT B Scans

Wide-Field OCT: By montaging multiple B-scans, this technique provides a panoramic view of the retina, extending the assessment beyond the peripapillary area to the macula and peripheral retina, which is valuable for detecting localized damage[3].

Hand-Held OCT: These portable devices have enabled imaging in challenging clinical situations (e.g., bedridden patients, children) and in laboratory settings for animal models of glaucoma, maintaining cross-sectional imaging capabilities similar to benchtop systems[3].



Figure 5 Images from an Ultrawide Field OCT

High-Resolution Cellular Imaging

Adaptive Optics (AO): AO systems correct for optical aberrations in the eye, allowing for microscopic resolution. When combined with modalities like Scanning Laser Ophthalmoscopy (SLO) or OCT, AO enables direct visualization of individual retinal structures, including RGCs and nerve fiber bundles. This offers the potential to detect the earliest signs of glaucomatous damage at a cellular level[2].

Metabolic and Functional Imaging

Flavoprotein Fluorescence (FPF): This technique measures the autofluorescence of mitochondrial flavoproteins in RGCs. Elevated FPF signals indicate cellular metabolic stress and have shown promise in distinguishing glaucomatous eyes from healthy ones, potentially serving as a very early biomarker of the disease[4].



Figure 6. Showing Stages of FP in Different Stages of Glaucoma

Integration of Artificial Intelligence (AI)

AI and machine learning algorithms are being increasingly applied to imaging data. These systems can automate the detection of glaucomatous patterns, quantify progression over time with high sensitivity, and even calculate future risk scores, thereby assisting clinicians in diagnosis and management decisions.[5,9]



Figure 7. Scans from AO-OCT

IV. Discussion

The proliferation of new imaging techniques marks a paradigm shift in glaucoma care, moving the focus from functional loss to structural preservation. The results indicate that technologies like SS-OCT and AO-OCT provide a level of structural detail previously unattainable in vivo, allowing clinicians to appreciate nuances of ONH and RNFL damage that precede functional deficits[1,2].

The primary advantage of these techniques is their objectivity and reproducibility, reducing the variability inherent in subjective clinical assessments[7]. The ability of FPF to detect metabolic dysfunction presents a novel approach, potentially identifying "at-risk" eyes before structural thinning occurs[4]. Furthermore, the integration of AI addresses the challenge of interpreting complex, multi-parameter imaging data, offering a scalable solution for screening and monitoring in busy clinical practices[5].

However, challenges remain. The high cost of advanced equipment like AO and SS-OCT may limit their widespread adoption, particularly in resource-limited settings where the glaucoma burden is highest. The diagnostic variability between different imaging platforms also necessitates careful interpretation[8]. While these techniques excel at detecting structure, the correlation between specific structural changes and their functional impact on a patient's quality of life is an area requiring continued research[1].

Despite these challenges, the potential impact on glaucoma management is profound. These imaging tools can guide more personalized treatment strategies, enable earlier intervention, and provide robust endpoints for clinical trials evaluating new IOP-lowering and neuroprotective therapies[1,8]

V. Conclusion

New imaging techniques for glaucoma have significantly advanced our ability to diagnose and monitor the disease. From high-penetration OCT to cellular-level AO imaging and metabolic stress detection, these technologies offer unprecedented insights into glaucomatous pathology. They empower a more proactive, structure-based approach to management, holding the promise of preventing vision loss by facilitating intervention at the earliest possible stage. Future efforts should focus on improving accessibility, standardizing measurements across platforms, and further validating the role of these technologies in predicting functional outcomes.

References

[1]. Weinreb RN, Aung T, Medeiros FA. The Pathophysiology And Treatment Of Glaucoma: A Review. JAMA. 2014 May 14;311(18):1901-11.

[2]. Rodriguez-Una I, Azuara-Blanco A. New Technologies For Glaucoma Detection. Asia Pac J Ophthalmol (Phila). 2018 Nov-Dec;7(6):394-404.

[3]. Kotowski J, Wollstein G, Folio LS, Ishikawa H, Schuman JS. Clinical Use Of OCT In Assessing Glaucoma Progression. Ophthalmic Surg Lasers Imaging. 2011 Oct;42 Suppl:S6-S14.

[4]. Chen AX, Conti TF, Hom GL, Greenlee TE, Raimondi R, Briskin IN, Et Al. Functional Imaging Of Mitochondria In Retinal Diseases Using Flavoprotein Fluorescence. Eye (Lond). 2021 Jan;35(1):74-92.

[5]. Jun TJ, Eom Y, Kim D, Kim C Et Al. Trk-CNN: Transferable Ranking-CNN For Image Classification Of Glaucoma, Glaucoma Suspect, And Normal Eyes. Arxiv Preprint Arxiv:1905.06509. 2019.

[6]. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Et Al. The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays Or Prevents The Onset Of Primary Open-Angle Glaucoma. Arch Ophthalmol. 2002 Jun;120(6):701-13.

[7]. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M; Early Manifest Glaucoma Trial Group. Reduction Of Intraocular Pressure And Glaucoma Progression: Results From The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79.
[8]. Usgaonkar UPS, Naik R, Shetty A. The Economic Burden Of Glaucoma On Patients. Indian J Ophthalmol. 2023 Feb;71(2):560-566.
[9]. Joon Jun T, Eom Y, Kim D, Kim C Et Al. Trk-CNN: Transferable Ranking-CNN For Image Classification Of Glaucoma, Glaucoma Suspect, And Normal Eyes. 2019
[10]. Omaka AU, Ezeigbo AC. RNFL Analysis With Scanning Laser Polarimeter. JNOA 2025; 27(1):38-51